Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Plos Pathogens|September 20, 2018
Circulating HLA-DR+CD4+ effector memory T cells resistant to CCR5 and PD-L1 mediated suppression compromise regulatory T cell function in tuberculosisAsma Ahmed, Vasista Adiga, Soumya Nayak, et al.
Plos One|December 9, 2017
Deep sequencing of near full-length HIV-1 genomes from plasma identifies circulating subtype C and infrequent occurrence of AC recombinant form in Southern IndiaShuba Varshini Alampalli, Michael M Thomson, Raghavan Sampathkumar, et al.
IJID Regions|April 3, 2025
Safety and immunogenicity of Biological E's typhoid conjugate vaccine TYPHIBEV<sup>Ⓡ</sup> concomitantly administered with measles rubella vaccine: a phase IV prospective, multicenter studySubhash Thuluva, Ramesh V Matur, SubbaReddy Gunneri, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2021
Sialoglycan recognition is a common connection linking acidosis, zinc, and HMGB1 in sepsisShoib S Siddiqui, Chirag Dhar, Venkatasubramaniam Sundaramurthy, et al.
The Lancet Regional Health. Southeast Asia|August 1, 2025
Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5-80 years in India: a phase 3, single-blind, randomised controlled trialSubhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, et al.
IJID Regions|January 19, 2026
Corrigendum to 'Immunogenicity and safety of Biological E's CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A Prospective double-blind randomised phase III clinical study' [IJID Regions, volume 17 (2025) 100786]Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, et al.
The Lancet Regional Health. Southeast Asia|March 11, 2026
Immunogenicity and safety of biological E's 14-valent pneumococcal conjugate vaccine (PNEUBEVAX 14®) administered in a 2p + 1 schedule to healthy infants: a multicenter, randomized, active controlled, single-blind, phase III trialSubhash Thuluva, Ramesh V Matur, Subbareddy Gunneri, et al.
IJID Regions|November 17, 2025
Immunogenicity and safety of Biological E's CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A prospective double-blind randomized phase III clinical studySubhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, et al.
Scientific Reports|September 22, 2017
Circulating Mycobacterium tuberculosis DosR latency antigen-specific, polyfunctional, regulatory IL10<sup>+</sup> Th17 CD4 T-cells differentiate latent from active tuberculosisSrabanti Rakshit, Vasista Adiga, Soumya Nayak, et al.
British Journal of Cancer|April 24, 2024
Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profilingChirag Dhar, Prasanna Ramachandran, Gege Xu, et al.
Pageof 3